Fusion of HSA influences TNF-α neutralizing activity of shTNFRs

Biotechnology Letters

Volumn 34, Issue 3, 2012, Pages 417-423

  Zhan, Jia ^a   Chen, Ying ^a   Yuan, Han Ying ^a   Li, Hai ^b   Lu, Hong ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Fusion protein; Human serum albumin; Tumor necrosis factor receptor

Indexed keywords

AUTOIMMUNE DISEASE; C-TERMINUS; CLINICAL INVESTIGATION; CLINICAL USAGE; CROHN'S DISEASE; CYTOLYTIC ACTIVITIES; FUSION PROTEINS; FUSION TECHNOLOGY; HALF LIVES; HUMAN SERUM ALBUMINS; HUMAN TUMORS; IN-VIVO; PICHIA PASTORIS; PROTEIN DRUGS; RHEUMATOID ARTHRITIS; TRANSPLANT REJECTION; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTORS;

BODY FLUIDS; DISEASE CONTROL; DISEASES; GLYCOPROTEINS; MACROPHAGES; TUMORS;

PROTEINS;

HYBRID PROTEIN; IMMUNOLOGIC FACTOR; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; CELL LINE; DRUG ANTAGONISM; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; PICHIA; SERODIAGNOSIS;

CELL LINE; GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; NEUTRALIZATION TESTS; PICHIA; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; TUMOR NECROSIS FACTOR-ALPHA;

PICHIA PASTORIS;

EID: 84856551249     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-011-0793-3     Document Type: Article

References (21)

1. Adams AE, Zwicker J, Curiel C et al (2004) Aggressive cutaneous T-cell lymphomas after TNF-α blockade. J Am Acad Dermatol 51: 660-662.
2. Aderka D, Engelmann H, Shemer-Avni I et al (1992) Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 10: 157-159.
3. Barone D, Krantz C, Lambert D et al (1999) Comparative analysis of the ability of etanercept and infliximab to lyse TNE-expressing cells in a complement dependent fashion. Arthr Rheum 42: 369-375.
4. Belew M et al (2008) Purification of recombinant human serum albumin (rhsa) produced by genetically modified Pichia pastoris. Sep Sci Technol 43: 3134-3153.
5. Cereghino JL, Cregg JM (2000) Heterologous protein expression in the methylotrophic yeast Picha pastoris. FEMS Microbiol Rev 24: 45-66.
6. Chang SH, Gong X, Yang ZY et al (2006) Over-expression in Picha pastoris and properties of human serum albumin-interferon α2b chimera. Chin J Biotechnol 22(2): 173-179.
7. Chuang VT, Kragh-Hansen U, Otagiri M (2002) Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 19(5): 569-577.
8. Cregg JM, Vedvick TS, Raschke WC (1993) Recent advances in the expression of foreign genes in Pichia pastoris. Bio/Technology 11(8): 905-910.
9. Dayer JM (2002) The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Jt Bone Spine 69: 123-132.
10. Garrison L, McDonnell ND (1999) Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 58(Suppl I): 165-169.
11. Halpern W, Riccobene TA, Agostini H et al (2002) Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res 19(11): 1720-1729.
12. He YP, Yin BJ, Li ZY et al (2003) The effect of TNF receptor blocking peptide on the functions of rat peritoneal macrophages. Chin J Immunol 19: 385-387 391.
13. Kobayashi K (2006) Summary of recombinant human serum albumin development. Biologicals 34(1): 55-59.
14. Orlinick JR, Chao MV (1998) TNF-related ligands and their receptors. Cell Signal 10: 543-551.
15. Osborn BL, Olsen HS, Nardelli B et al (2002) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303(2): 540-548.
16. Srivastava MD (2001) Immunomodulatory effects of etanercept (TNFR: FC) and its use in a patient with Crohn's disease. Res Commun Mol Pathol Pharmacol 109(1-2): 125-141.
17. Sung C, Nardelli B, LaFleur DW et al (2003) An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J Interferon Cytokine Res 23(1): 25-36.
18. Vermeire S, Noman M, Assche GV et al (2001) Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation. Gastroenterology 120: A69.
19. Wang TY, Wang CH M, Wei G et al (2001) Acta Biochim Biophys Sinca 33(6): 659-664.
20. Zhang G (2004) Tumor necrosis factor family ligand-receptor binding. Curr Opin Struct Biol 14: 154-160.
21. Zhao HL, Xue C, Wang Y et al (2007) Circumventing the heterogeneity and instability of human serum albumin-interferon-α2b fusion protein by altering its orientation. J Biotechnol 131(3): 245-252.